BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17348259)

  • 1. Patents, biomedical research, and treatments: examining concerns, canvassing solutions.
    Johnston J; Wasunna AA;
    Hastings Cent Rep; 2007; 37(1):S1-36. PubMed ID: 17348259
    [No Abstract]   [Full Text] [Related]  

  • 2. A modest proposal: toward improved access to biotechnology research tools by implementing a broad experimental use exception.
    Hoffman DC
    Cornell Law Rev; 2004 May; 89(4):993-1043. PubMed ID: 15174465
    [No Abstract]   [Full Text] [Related]  

  • 3. Rights, patents, markets and the global AIDS pandemic.
    Gathii JT
    Fla J Int Law; 2002; 14(2):261-352. PubMed ID: 16526139
    [No Abstract]   [Full Text] [Related]  

  • 4. Alienation from the Objectives of the Patent System: How to Remedy the Situation of Biotechnology Patent.
    Jiang L
    Sci Eng Ethics; 2019 Jun; 25(3):791-811. PubMed ID: 29532279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Patent rights and the free research. The boundary between basic research and private sector is not longer razor-sharp].
    Westerlund L
    Lakartidningen; 2005 Sep 26-Oct 2; 102(39):2737. PubMed ID: 16245544
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of the private sector in biotechnology: research and development.
    Feisee L
    Health Matrix Clevel; 2002; 12(2):357-65. PubMed ID: 12430359
    [No Abstract]   [Full Text] [Related]  

  • 7. European opposition to exclusive control over predictive breast cancer testing and the inherent implications for U.S. patent law and public policy: a case study of the Myriad Genetics' BRCA patent controversy.
    Paradise J
    Food Drug Law J; 2004; 59(1):133-54. PubMed ID: 15190928
    [No Abstract]   [Full Text] [Related]  

  • 8. In search of a compromised solution to the problem arising from patenting biomedical research tools.
    Derzko NM
    Santa Clara Comput High Technol Law J; 2004; 20(2):347-410. PubMed ID: 16493840
    [No Abstract]   [Full Text] [Related]  

  • 9. The scope of utility in the twenty-first century: new guidance for gene-related patents.
    Summers TM
    Georgetown Law J; 2003 Jan; 91(2):475-509. PubMed ID: 15046071
    [No Abstract]   [Full Text] [Related]  

  • 10. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS
    N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract]   [Full Text] [Related]  

  • 11. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
    Berger JM
    Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
    [No Abstract]   [Full Text] [Related]  

  • 12. Intellectual property and biotechnology: the U.S. internal experience--Part I.
    Brody B
    Kennedy Inst Ethics J; 2006 Mar; 16(1):1-37. PubMed ID: 16770885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential AIDS medications in India.
    Thomas J
    Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
    [No Abstract]   [Full Text] [Related]  

  • 14. Who owns what? Private ownership and the public interest in recombinant DNA technology in the 1970s.
    Yi D
    Isis; 2011 Sep; 102(3):446-74. PubMed ID: 22073770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Science and the law. Working through the patent problem.
    Walsh JP; Cohen WM; Arora A
    Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME
    Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
    [No Abstract]   [Full Text] [Related]  

  • 17. Intellectual property and biotechnology: the U.S. internal experience--Part II.
    Brody B
    Kennedy Inst Ethics J; 2006 Jun; 16(2):105-28. PubMed ID: 17036443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 19. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
    Spectar JM
    Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
    [No Abstract]   [Full Text] [Related]  

  • 20. Health innovation networks to help developing countries address neglected diseases.
    Morel CM; Acharya T; Broun D; Dangi A; Elias C; Ganguly NK; Gardner CA; Gupta RK; Haycock J; Heher AD; Hotez PJ; Kettler HE; Keusch GT; Krattiger AF; Kreutz FT; Lall S; Lee K; Mahoney R; Martinez-Palomo A; Mashelkar RA; Matlin SA; Mzimba M; Oehler J; Ridley RG; Senanayake P; Singer P; Yun M
    Science; 2005 Jul; 309(5733):401-4. PubMed ID: 16020723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.